{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-007705","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.898425+00:00","generated_at":"2026-05-27T07:12:45.417848+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OS Therapies acquires Ayala's listeria IP for $8M, eliminates milestones, adds Phase 2 lung asset","bullets":["Total consideration $8M: $0.5M cash + $7.5M in OSTX shares; 180-day lock-up. Closes ~60 days.","Eliminates $3.5M BLA milestone and $16.5M in OST-HER2 sales milestones; royalty reduced from 10% to 1.5% under Penn License.","Adds Phase 2 ADXS-503 (NSCLC) and Phase 1 ADXS-504 (prostate) programs using Listeria monocytogenes platform.","Karim Galzahr appointed to board; managing partner at OKG Capital, over 30 yrs finance experience.","Company has $7.1M financing at $4/share; cash runway into 2026; no equity raises below $12 for 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-007705","json":"https://secwatch.observer/filing/0001213900-25-007705.json","markdown":"https://secwatch.observer/filing/0001213900-25-007705.md","text":"https://secwatch.observer/filing/0001213900-25-007705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/0001213900-25-007705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/ea0229055-8k_osthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:12:45.417848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bfb7fd8f4","claim":"Karim Galzahr was elected as Director at OS Therapies Inc.","evidence_excerpt":"On January 28, 2025, Karim Galzahr was elected to the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/0001213900-25-007705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}